AN2 Therapeutics (ANTX) vs Oramed Pharmaceuticals (ORMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Oramed Pharmaceuticals (ORMP) over the past year, gaining 270.2% versus a gain of 76.2%. AN2 Therapeutics is the larger company by market cap ($183.0 million vs $181.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | ORMP |
|---|---|---|
| Share price | $4.85 | $4.37 |
| Market cap | $183.02M | $181.78M |
| 1-day change | -4.34% | -0.23% |
| YTD return | +325.44% | +53.33% |
| 1-year return | +270.23% | +76.21% |
| 5-year return | — | -80.19% |
| P/E ratio (TTM) | — | 1.06 |
| EPS (TTM) | $-1.00 | $4.13 |
| Dividend yield | 0.00% | 5.71% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $5.47 |
| 52-week low | $1.00 | $2.09 |
| Distance from 52-week high | -32.55% | -20.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +85.57% | +60.18% |
| Average volume | 237.78K | 194.48K |
| Shares outstanding | 37.74M | 41.60M |
| Employees | 21 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed ORMP by 194.0 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (5.71% vs 0.00%).
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Healthcare · Biotechnology · 21 employees
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Healthcare · Biotechnology
ANTX vs ORMP FAQ
Which is bigger, AN2 Therapeutics or Oramed Pharmaceuticals?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $183.02M compared with $181.78M for Oramed Pharmaceuticals (ORMP).
Which stock has performed better over the past year, ANTX or ORMP?
ANTX returned +270.23% over the past 12 months, compared with +76.21% for ORMP (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, AN2 Therapeutics or Oramed Pharmaceuticals?
Oramed Pharmaceuticals pays a dividend yielding 5.71%, while AN2 Therapeutics does not currently pay a regular dividend.
Are AN2 Therapeutics and Oramed Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.